Abstract:Recent studies confirm that chronic low-grade inflammation is closely associated with metabolic syndromes, and anti-inflammatory therapy is a potential approach for treating cardiovascular diseases and type 2 diabetes. Accumulating evidence suggests that GPR120 activation is a feasible solution to ameliorating chronic inflammation and improving glucose metabolism. In this study we investigated whether ginsenoside Rb2 (Rb2), which exhibited regulatory activities in glucose and lipid metabolism, affected GPR120 expression in lipopolysaccharide (LPS)-activated mouse macrophage RAW264.7 cells, and examined the contribution of GPR120 activation to reducing the LPS-induced inflammatory response. LPS (100 ng/mL) activated the macrophages, resulting in dramatic increases in TNF-α, IL-6, IL-1β and NO production. Treatment with a ω-3 fatty acid α-linolenic acid (ALA, 50 μmol/L) produced moderate reduction in LPS-stimulated inflammatory cytokines and NO production (TNF-α and IL-6 were decreased by 46% and 42%, respectively). Pre-incubation with Rb2 (1 or 10 μmol/L) for 12 h before ALA treatment dramatically amplified the inhibitory effects of ALA (TNF-α and IL-6 were decreased by 74% and 86%, respectively). Compared to the treatment with ALA alone, pre-incubation with Rb2 resulted in a more prominent reduction in LPS-stimulated expression of iNOS and COX-2 and LPS-stimulated IKK/NF-κB phosphorylation and MAPK pathway activation. Rb2 (0.1-100 μmol/L) dose- and time-dependently increased both mRNA and protein expression of GPR120 in RAW264.7 cells, but treatment with Rb2 alone did not exert anti-inflammatory effect in LPS-activated RAW264.7 cells. In RAW264.7 cells transfected with GPR120 shRNA, the ameliorating effects of Rb2 on LPS-induced inflammation were abolished. In conclusion, Rb2 exerts anti-inflammatory effect in LPS-stimulated mouse macrophage RAW264.7 cells in vitro by increasing GPR120 expression and subsequently enhancing ω-3 fatty acid-induced GPR120 activation.

Ginsenoside Rh2 Downregulates LPS-Induced NF-κB Activation Through Inhibition of TAK1 Phosphorylation in RAW 264.7 Murine Macrophage

Ginsenoside Rh2 Alleviates LPS-Induced Inflammatory Responses by Binding to TLR4/MD-2 and Blocking TLR4 Dimerization

Sulfated Derivative of 20(S)-Ginsenoside Rh2 Inhibits Inflammatory Cytokines Through MAPKs and NF-kappa B Pathways in LPS-Induced RAW264.7 Macrophages

Inhibitory Effects of Sulfated 20(S)-Ginsenoside Rh2 on the Release of Pro-Inflammatory Mediators in LPS-induced RAW 264.7 Cells.

Ginsenoside Rk1 Suppresses Pro-Inflammatory Responses in Lipopolysaccharide-Stimulated Raw264.7 Cells by Inhibiting the Jak2/Stat3 Pathway

Anti-Inflammatory Effects of Ginsenoside Rb3 in LPS-Induced Macrophages Through Direct Inhibition of TLR4 Signaling Pathway

Protective effects of ginsenoside-Rg2 and -Rh1 on liver function through inhibiting TAK1 and STAT3-mediated inflammatory activity and Nrf2/ARE-mediated antioxidant signaling pathway

Ginsenoside Rg3 suppresses the NLRP3 inflammasome activation through inhibition of its assembly

Ginsenoside Rg1 Improves Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting Inflammatory Responses and Modulating Infiltration of M2 Macrophages

Ginsenoside Rg3 regulates S-nitrosylation of the NLRP3 inflammasome via suppression of iNOS

Ginsenoside Rb1 Exerts Anti-Inflammatory Effects in Vitro and in Vivo by Modulating Toll-Like Receptor 4 Dimerization and NF-kB/MAPKs Signaling Pathways.

Inhibitory Effect of Ginsenoside Rg1 on Lipopolysaccharide-Induced Microglial Activation in Mice

Ginsenoside Rb2 enhances the anti-inflammatory effect of ω-3 fatty acid in LPS-stimulated RAW264.7 macrophages by upregulating GPR120 expression

Integrative network pharmacology and experimental verification to reveal the anti-inflammatory mechanism of ginsenoside Rh4

Ginsenoside Rg1 protects human renal tubular epithelial cells from lipopolysaccharide-induced apoptosis and inflammation damage

Panax notoginseng attenuates LPS-induced pro-inflammatory mediators in RAW264.7 cells

Differential effects of ginsenosides on NO and TNF-alpha production by LPS-activated N9 microglia.

Lipopolysaccharide-induced Inflammation is Inhibited by Ginsenoside Re Through NF-kappa B Signaling in RAW264.7 Cells and Primary Rat Hepatocytes

Ginsenoside Rb1 alleviates lipopolysaccharide‐induced inflammation in human dental pulp cells via the PI3K/Akt, NF‐κB, and MAPK signalling pathways

The Ginsenoside Rd Suppresses Lps-Induced Inflammation And Nf-Kappa B Activation In Colon Cancer Cells

Suppression of MAPKs/NF-κB Activation Induces Intestinal Anti-Inflammatory Action of Ginsenoside Rf in HT-29 and RAW264.7 Cells